Bionano Genomics, Inc. (NASDAQ:BNGO) H.C. Wainwright 24th Annual Global Investment Conference September 12, 2022 7:00 AM ET Company Participants Erik Holmlin - President and Chief Executive Officer Conference Call Participants Trevor Levy - H.C. Wainwright Trevor Levy Good afternoon, everyone. And thank you for joining the H.C. Wainwright 24th Annual Global Investment Hybrid Conference. My name is Trevor Levy and I'm on the Corporate Access Team at HC Wainwright. While we are hybrid this year, we're confide ...

Bionano Genomics, Inc. (NASDAQ:BNGO) Q2 2022 Results Conference Call August 4, 2022 4:30 PM ET Company Participants Amy Conrad - Investor Relations Erik Holmlin - Chief Executive Officer Christopher Stewart - Chief Financial Officer Conference Call Participants Michael Okunewitch - Maxim Group Operator Good day and welcome to the Bionano Genomics’ Second Quarter 2022 Earnings Conference Call. Today's conference is being recorded. At this time, I would like to turn the conference over to Amy Conrad from Inve ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _________________________________________________________ FORM 10-Q _________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO | --- | --- | --- | --- | ...

Bionano Genomics, Inc. (NASDAQ:BNGO) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Amy Conrad - Investor Relations Erik Holmlin - Chief Executive Officer Chris Stewart - Chief Financial Officer Conference Call Participants Michael Okunewitch - Maxim Group Operator Good day, and welcome to the Bionano Genomics First Quarter 2022 Earnings Conference Call. Today's conference is being recorded. At this time, I would like to turn the conference over to Amy Conrad from Investor Rel ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _________________________________________________________ FORM 10-Q _________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO | --- | --- | --- | |--- ...

Summary of Bionano Genomics, Inc. Conference Call Company Overview - **Company**: Bionano Genomics, Inc. (NASDAQ:BNGO) - **Industry**: Genomics and Biotechnology - **Technology**: Optical Genome Mapping (OGM) Key Points and Arguments 1. **Commercial Progress**: Bionano Genomics achieved $80 million in revenues for the previous year and installed 164 Saphyr systems, exceeding their goal of 150, representing a 65% year-over-year growth in the installed base [4][33] 2. **Adoption of Technology**: The company doubled the number of consumable flow cells sold, indicating a growing adoption of their methodology and systems for in-house genome analysis [4] 3. **Acquisition of BioDiscovery**: The acquisition of BioDiscovery, which developed the NxClinical software, is aimed at integrating optical genome mapping data with next-generation sequencing, enhancing customer experience and driving commercial adoption [5] 4. **Complementarity with Sequencing**: Bionano emphasizes that OGM complements rather than competes with next-generation sequencing, providing a more comprehensive view of the genome [5][11] 5. **Resolution Improvement**: OGM increases the resolution of structural variation detection from 5 million base pairs (karyotyping) to 500 base pairs, which is critical for cancer testing and genetic diseases [10] 6. **Clinical Utility**: The technology has been shown to find significantly more pathogenic variants, with studies indicating double-digit percentage increases in detection rates compared to traditional methods [21] 7. **Workflow Automation**: NxClinical automates the integration of optical genome mapping with sequencing, significantly speeding up the process of generating reportable results [19] 8. **Future of Cytogenetics**: Bionano positions OGM as the future of cytogenetics, suggesting it will replace traditional methods like karyotyping and FISH in many applications [25][28] 9. **Market Focus**: The company is targeting academic medical centers for adoption, emphasizing the need for reimbursement pathways to facilitate broader use of OGM [30] 10. **2022 Goals**: Bionano aims to increase the installed base from 164 to 240 systems by the end of 2022 and is focusing on obtaining a Category One CPT code for reimbursement [33] Additional Important Content - **Clinical Testing Challenges**: 50% to 70% of clinical tests for genetic diseases and cancer return no pathogenic variant findings, highlighting the need for higher resolution methods like OGM [21] - **Real-World Applications**: Examples from clinical settings, such as the Children's Hospital of LA, demonstrate how OGM can identify druggable targets in pediatric cancers that traditional sequencing might miss [22][23] - **Integration of Technologies**: The integration of OGM with existing workflows is seen as a way to streamline processes and improve diagnostic capabilities in laboratories [27][30] This summary encapsulates the key insights and developments discussed during the conference call, highlighting Bionano Genomics' strategic direction and the potential impact of its technology in the genomics field.

Bionano Genomics, Inc. (NASDAQ:BNGO) Q4 2021 Earnings Conference Call March 1, 2022 4:30 PM ET Company Participants Amy Conrad – Investor Relations Erik Holmlin – Chief Executive Officer Chris Stewart – Chief Financial Officer Conference Call Participants Sung Ji Nam – BTIG Destiny Buch – Ladenburg Thalmann Kevin DeGeeter – Oppenheimer Michael Okunewitch – Maxim Group Operator Good day, and welcome to the Bionano Genomics Fourth Quarter and Full Year 2021 Earnings Conference Call. Today’s conference is bein ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM Commission File Number 001-38613 Bionano Genomics, Inc. | --- | --- | |-------------------------------------------------------------------------- ...

Bionano Genomics, Inc. (NASDAQ:BNGO) Q3 2021 Earnings Conference Call November 4, 2021 4:30 PM ET Company Participants Amy Conrad - Investor Relations Erik Holmlin - Chief Executive Officer Chris Stewart - Chief Financial Officer Rich Shippy - CBO Conference Call Participants Destiny Buch - Ladenburg Thalmann Kevin DeGeeter - Oppenheimer Operator Good day, and welcome to the Bionano Genomics' Third Quarter 2021 Earnings Conference Call. Today's conference is being recorded. At this time, I'd like to turn th ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _________________________________________________________ FORM 10-Q _________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file numb ...